Amivantamab (FUT8-KO) is a humanized dual-specificity antibody targeting EGFR-MET, with FUT8 knocked out, exhibiting immunotherapeutic anticancer activity. This compound inhibits ligand binding, enhances the internalization and degradation of receptor-antibody complexes, and stimulates macrophage-mediated phagocytosis and natural killer cell cytotoxicity, both of which are Fc-dependent.
Molecular Weight:
232.23
Formula:
C13H12O4
Target:
EGFR
T9901A-232
* VAT and and shipping costs not included. Errors and price changes excepted
